Key Points
- CEO Joshua Silverman purchased 40,000 shares of Nuvilex on Jan. 7 at $0.83 (about $33,200), raising his holdings to 416,250 shares — a 10.63% increase; he also bought 30,000 shares on Jan. 5 at $0.78.
- Nuvilex trades around $0.83 with a market cap of $8.41 million, reported a loss of $0.32 EPS last quarter, and carries an average analyst rating of Sell.
Nuvilex Inc. (NASDAQ:PMCB - Get Free Report) Director Jonathan Schechter purchased 20,000 shares of the firm's stock in a transaction dated Monday, January 5th. The stock was bought at an average cost of $0.78 per share, for a total transaction of $15,600.00. Following the acquisition, the director directly owned 152,500 shares in the company, valued at approximately $118,950. The trade was a 15.09% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
Jonathan Schechter also recently made the following trade(s):
- On Wednesday, January 7th, Jonathan Schechter acquired 20,000 shares of Nuvilex stock. The shares were bought at an average cost of $0.84 per share, with a total value of $16,800.00.
Nuvilex Stock Performance
Shares of NASDAQ:PMCB opened at $0.83 on Thursday. The firm has a market capitalization of $8.41 million, a PE ratio of -0.60 and a beta of 0.04. Nuvilex Inc. has a 52-week low of $0.63 and a 52-week high of $1.90. The firm has a fifty day moving average of $0.84 and a 200 day moving average of $0.95.
Nuvilex (NASDAQ:PMCB - Get Free Report) last released its quarterly earnings results on Thursday, December 18th. The company reported ($0.32) earnings per share for the quarter.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Nuvilex in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Nuvilex presently has a consensus rating of "Sell".
Get Our Latest Analysis on PMCB
About Nuvilex
(
Get Free Report)
PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
